Sphere-9 Catheter and Affera Ablation System
Medtronic, Inc. · Decision date Oct 2, 2026
What did the FDA approve?
The FDA record for P240013/S031 lists a real-time process supplement for labeling changes to the Sphere-9 Catheter and Affera Ablation System, a percutaneous cardiac ablation catheter for treating atrial fibrillation with irreversible electroporation. The listed statement describes the action only as "for changes to the instructions for use (IFU)," and the supplement reason names modifications to indications, instructions, shelf life, or tradename.
The identifier links this supplement to PMA P240013, but the decision applies to a supplement rather than a new approval of the whole system. The record does not specify which IFU section changed, whether indications were modified, or what the changed text says. Nothing here independently establishes safety, clinical effectiveness, or a new indication; the reported purpose is labeling, not evidence.
FDA approval order statement
for changes to the instructions for use (IFU)
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 2, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240013/S031
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic, Inc.
- Product code
- QZI
- Decision code
- APPR
- Decision date
- Oct 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.
- Applicant
- Medtronic, Inc.
- Product code
- QZI
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240013. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240013 · Original PMA
Sphere-9 Catheter and Affera Ablation System
P240013/S031 received
Application receipt date recorded by FDA.
P240013/S031 · FDA decision
Real-Time Process
P240013/S028 · Related supplement
Sphere-9 Catheter and Affera Ablation System
P240013/S032 · Related supplement
Affera Sphere-9 Mapping and Ablation Catheter
Timeline entries are records held by MedtechLedger for P240013. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240013
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic, Inc. | PMA approval | Oct 24, 2024 | FDA | |
Sphere-9 Catheter and Affera Ablation SystemP240013/S028 | Medtronic, Inc. | PMA supplement | Oct 6, 2026 | FDA |
Affera Sphere-9 Mapping and Ablation CatheterP240013/S032 | Medtronic, Inc. | PMA supplement | Oct 9, 2026 | FDA |
Explore the linked device profile
Other records with product code QZI
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Varipulse Bi-Directional CatheterP240006/S018 | Biosense Webster, Inc. | PMA supplement | Nov 3, 2026 | FDA |
Globe Catheter and Globe Pulsed Field SystemP240044/S007 | Kardium, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Globe Pulsed Field System; Globe CatheterP240044/S008 | Kardium, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Volt PFA SystemP250022/S002 | ABBOTT MEDICAL | PMA supplement | Oct 15, 2026 | FDA |
Volt PFA Catheter, Sensor EnabledP250022/S009 | ABBOTT MEDICAL | PMA supplement | Oct 8, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 8200 Coral Sea St. N.E, Mounds View, MN, 55112
Sources and methodology
- Original FDA record: P240013/S031
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
